Dimitrios T Trafalis
Overview
Explore the profile of Dimitrios T Trafalis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
905
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anestopoulos I, Paraskevaidis I, Kyriakou S, Giova L, Trafalis D, Botaitis S, et al.
Int J Mol Sci
. 2024 Mar;
25(5).
PMID: 38473991
In this study, we utilized an in vitro model consisting of human malignant melanoma as well as non-tumorigenic immortalized keratinocyte cells with the aim of characterizing the therapeutic effectiveness of...
2.
Orfanakos K, Alifieris C, Verigos E, Deligiorgi M, Verigos K, Panayiotidis M, et al.
Biomedicines
. 2024 Jan;
12(1).
PMID: 38255239
Ionizing radiation is strongly linked to direct or indirect DNA damage, as with the production of reactive oxygen species (ROS), which in turn produce DNA damage products, such as 8-hydroxy-2-deoxyguanosine...
3.
Kyriakou S, Tragkola V, Paraskevaidis I, Plioukas M, Trafalis D, Franco R, et al.
Plants (Basel)
. 2023 Apr;
12(8).
PMID: 37111814
Malignant melanoma is an aggressive type of skin cancer characterised by high metastatic capacity and mortality rate. On the other hand, is known for its medicinal properties, including its anticancer...
4.
Deligiorgi M, Trafalis D
Int J Mol Sci
. 2023 Apr;
24(8).
PMID: 37108792
The rubric of immune-related (ir) diabetes mellitus (DM) (irDM) encompasses various hyperglycemic disorders related to immune checkpoint inhibitors (ICPis). Beyond sharing similarities with conventional DM, irDM is a distinct, yet...
5.
Sflakidou E, Dalezis P, Trafalis D, Sarli V
Eur J Med Chem
. 2023 Jan;
249:115133.
PMID: 36696765
Alkylating agents are potent anticancer compounds that exert their anticancer properties through the inhibition of cell replication and transcription leading to cell death. Despite the numerous benefits, these agents also...
6.
Varna D, Geromichalou E, Karlioti G, Papi R, Dalezis P, Hatzidimitriou A, et al.
Molecules
. 2023 Jan;
28(1).
PMID: 36615533
Ag(I) coordination compounds have recently attracted much attention as antiproliferative and antibacterial agents against a wide range of cancer cell lines and pathogens. The bioactivity potential of these complexes depends...
7.
Kyriakou S, Michailidou K, Amery T, Stewart K, Winyard P, Trafalis D, et al.
Front Plant Sci
. 2022 Dec;
13:998755.
PMID: 36457522
Watercress () is a rich source of secondary metabolites with disease-preventing and/or health-promoting properties. Herein, we have utilized extraction procedures to isolate fractions of polyphenols, glucosinolates and isothiocyanates to determine...
8.
Deligiorgi M, Trafalis D
Per Med
. 2022 Dec;
20(1):87-105.
PMID: 36454100
Hypothyroidism in the setting of cancer is a puzzling entity due to the dual role of the thyroid hormones (TH) in cancer - promoting versus inhibitory - and the complexity...
9.
Deligiorgi M, Trafalis D
Expert Rev Clin Pharmacol
. 2022 Jun;
15(5):531-549.
PMID: 35757870
Introduction: Hypothyroidism is a common adverse event of various anticancer treatment modalities, constituting a notable paradigm of the integration of the endocrine perspective into precision oncology. Areas Covered: The present...
10.
Deligiorgi M, Trafalis D
J Clin Med
. 2022 Jun;
11(12).
PMID: 35743483
Hypothyroidism in patients with solid non-thyroid cancer is a tantalizing entity, integrating an intriguing thyroid hormones (THs)-cancer association with the complexity of hypothyroidism itself. The present narrative review provides a...